Articles

Discovery and development of new medicines to extend or improve the life of patients is a challenging and expensive endeavor. The cost of developing a new drug is estimated to be between $800 million and $2 billion and often requires 10 or more years of development with the FDA only approving, on average, 30 new ...

Since its founding in 2013, Enteris BioPharma, a clinical-stage biopharmaceutical company based in Boonton, NJ, has grown into an important player in the drug development and delivery market by utilizing its proprietary drug delivery technologies, Peptelligence® and ProPermaTM, to develop and produce oral formulations of BCS class III and IV compounds, including peptides, peptidomimetics, and ...

Proteins and peptides are the building blocks of life and are a very promising basis for targeting a range of diseases. Throughout the past 30 years, and especially the past 10 years, there has been a rapid growth in the development of therapeutic proteins, with a significant increase in the number of protein-based drugs on ...

Breaking down the barriers to oral delivery of peptides and small molecules is no easy task, but it holds the key to enhancing myriad drug products and treatment paradigms.

Proteins and peptides are the building blocks of life and are a very promising basis for targeting a range of diseases. Throughout the past 30 years, and especially the past 10 years, there has been a rapid growth in the development of therapeutic proteins, with a significant increase in the number of protein-based drugs on ...